A Randomized, Double-Blind, Parallel-Group, 28-Week, Chronic-Dosing, Multi-Center, Extension Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) Compared With Symbicort Turbuhaler as an Active Control

Trial Profile

A Randomized, Double-Blind, Parallel-Group, 28-Week, Chronic-Dosing, Multi-Center, Extension Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) Compared With Symbicort Turbuhaler as an Active Control

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2018

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Budesonide/formoterol/glycopyrrolate (Primary) ; Formoterol/glycopyrrolate (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Sponsors Pearl Therapeutics
  • Most Recent Events

    • 24 Jul 2018 Status changed from active, no longer recruiting to completed.
    • 15 May 2018 Planned End Date changed from 13 Jul 2018 to 19 Jun 2018.
    • 15 May 2018 Planned primary completion date changed from 13 Jul 2018 to 19 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top